News/ News/ Oncology AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLC Phil Taylor AstraZeneca, CAR-T therapies, China, Gilead Sciences, HutchMed, immuno-oncology, lung cancer, Non-small cell lung cancer, Oncology, Orpathys, savolitinib, Yescarta 0 Comment AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share X AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLC https://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/